565 related articles for article (PubMed ID: 17440108)
21. Tumor therapy with bispecific antibody: the targeting and triggering steps can be separated employing a CD2-based strategy.
Wild MK; Strittmatter W; Matzku S; Schraven B; Meuer SC
J Immunol; 1999 Aug; 163(4):2064-72. PubMed ID: 10438945
[TBL] [Abstract][Full Text] [Related]
22. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
[TBL] [Abstract][Full Text] [Related]
23. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
24. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
[TBL] [Abstract][Full Text] [Related]
25. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.
Offner S; Hofmeister R; Romaniuk A; Kufer P; Baeuerle PA
Mol Immunol; 2006 Feb; 43(6):763-71. PubMed ID: 16360021
[TBL] [Abstract][Full Text] [Related]
26. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauss G; Gückel B; Wallwiener D; Moldenhauer G
Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
[TBL] [Abstract][Full Text] [Related]
27. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.
Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK
Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477
[TBL] [Abstract][Full Text] [Related]
28. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
Schirrmann T; Pecher G
Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
[TBL] [Abstract][Full Text] [Related]
30. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells.
Cho BK; Roy EJ; Patrick TA; Kranz DM
Bioconjug Chem; 1997; 8(3):338-46. PubMed ID: 9177839
[TBL] [Abstract][Full Text] [Related]
31. BiTEs: bispecific antibody constructs with unique anti-tumor activity.
Wolf E; Hofmeister R; Kufer P; Schlereth B; Baeuerle PA
Drug Discov Today; 2005 Sep; 10(18):1237-44. PubMed ID: 16213416
[TBL] [Abstract][Full Text] [Related]
32. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
[TBL] [Abstract][Full Text] [Related]
33. Bispecific antibody-mediated lysis of placental and germ cell alkaline phosphatase targeted solid tumors in immunocompetent mice.
Smans KA; Hoylaerts MF; Narisawa S; Millán JL; De Broe ME
Cancer Res; 1995 Oct; 55(19):4383-90. PubMed ID: 7671251
[TBL] [Abstract][Full Text] [Related]
34. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
Rohrbach F; Gerstmayer B; Biburger M; Wels W
Clin Cancer Res; 2000 Nov; 6(11):4314-22. PubMed ID: 11106249
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo properties of a dimeric bispecific single-chain antibody IgG-fusion protein for depletion of CCR2+ target cells in mice.
Schneider MA; Brühl H; Wechselberger A; Cihak J; Stangassinger M; Schlöndorff D; Mack M
Eur J Immunol; 2005 Mar; 35(3):987-95. PubMed ID: 15719369
[TBL] [Abstract][Full Text] [Related]
36. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
[TBL] [Abstract][Full Text] [Related]
37. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
[TBL] [Abstract][Full Text] [Related]
38. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases.
Penna C; Dean PA; Nelson H
Cancer Res; 1994 May; 54(10):2738-43. PubMed ID: 8168104
[TBL] [Abstract][Full Text] [Related]
39. Anti-CD3:anti-IL-2 receptor bispecific monoclonal antibody. Targeting of activated T cells in vitro.
MacLean JA; Su Z; Guo Y; Sy MS; Colvin RB; Wong JT
J Immunol; 1993 Feb; 150(4):1619-28. PubMed ID: 8432997
[TBL] [Abstract][Full Text] [Related]
40. Development of a novel bi-specific monoclonal antibody approach for tumour targeting.
Koumarianou AA; Hudson M; Williams R; Epenetos AA; Stamp GW
Br J Cancer; 1999 Oct; 81(3):431-9. PubMed ID: 10507767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
